{"id":"NCT04889118","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study","officialTitle":"A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (LEAP-003)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-14","primaryCompletion":"2023-01-18","completion":"2024-11-01","firstPosted":"2021-05-17","resultsPosted":"2024-07-09","lastUpdate":"2024-12-02"},"enrollment":131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Malignant Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Lenvatinib","otherNames":["MK-7902","E7080","LENVIMA®"]},{"type":"DRUG","name":"Placebo for lenvatinib","otherNames":[]}],"arms":[{"label":"Pembrolizumab+Lenvatinib","type":"EXPERIMENTAL"},{"label":"Pembrolizumab+Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the China Extension study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in Chinese participants with no prior systemic therapy for their advanced melanoma.","primaryOutcome":{"measure":"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"Up to approximately 30 months","effectByArm":[{"arm":"Pembrolizumab+Lenvatinib","deltaMin":6.1,"sd":null},{"arm":"Pembrolizumab+Placebo","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":29},"locations":{"siteCount":11,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":64},"commonTop":["Proteinuria","Hypertriglyceridaemia","Hypothyroidism","Weight decreased","Hypertension"]}}